“…TPCs express high levels of neuroendocrine differentiation compared to non-TPCs, including Ascl1 , a key oncogenic factor in SCLC (Augustyn et al, 2014; Jiang et al, 2009). Accordingly, treatment with a drug-conjugated antibody against DLL3, a transcriptional, target of ASCL1 (Nelson et al, 2009), was shown to inhibit the transplantation ability in human SCLC PDX models (Saunders et al, 2015). We focused on MYC based on its known oncogenic role in SCLC (Alves Rde et al, 2014; Calbo et al, 2005; George et al, 2015; Huijbers et al, 2014; Romero et al, 2014).…”